CareDx, Inc. (CDNA) News
Filter CDNA News Items
CDNA News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest CDNA News From Around the Web
Below are the latest news stories about CareDx Inc that investors may wish to consider to help them evaluate CDNA as an investment opportunity.
The Daily Biotech Pulse: Amag Spikes On Takeover Rumors, Zosano Wilts On Regulatory Setback, Pulmonx Makes Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Annexon Inc (NASDAQ: ANNX ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cardiff Oncology Inc (NASDAQ: CRDF ) CareDx Inc (NASDAQ: CDNA ) CTI BioPharma Corp (NASDAQ: CTIC ) I-Mab ADR (NASDAQ: IMAB ) Insulet Corporation (NASDAQ: PODD ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) LifeSci Acquisition Corp (NASDAQ: LSAC ) (the blank check company announced a business combination with oncology-focused Vincera Pharma) Mirati Th...
Transplant Diagnostics Market With Current Trends Analysis 2020: Omixon Ltd., CareDx, Affymetrix, Inc, Abbott Laboratories, Inc, Thermo Fisher Scientific, Inc
The Business Research Company offers " Transplant Diagnostics Global Market Report 2020-30: Covid 19 Growth And Change" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective
CareDx (CDNA): Q2 Non-GAAP EPS of $0.04 beats by $0.08; GAAP EPS of -$0.15 in-line.Revenue of $41.8M (+32.9% Y/Y) beats by $6.19M.Press Release...
SOUTH SAN FRANCISCO, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces today it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11-13, 2020. CareDx’s management is scheduled to present on Wednesday, August 12, 2020, at 1:00 p.m. EDT. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at investors.caredxinc.com. About CareDx CareDx, Inc., headquartered in South San Francisco, California, is a leading precision me...
Artificial intelligence (AI) is a buzzword in tech these days. The term, which encompasses a range of technologies including machine learning and data analysis. The goal is to create systems that can perceive, learn, and reason in ways that mimic human capabilities. At its best, AI will allow machines to understand the gestalt of a situation and react accordingly, a capability that humans take for granted – but has tended to elude computer systems, which in their turn excel at analyzing minute details.A wide range of tech companies are working on AI systems; artificial intelligence holds the promise of real-time data analysis and situation monitoring, with the machines capable of handling routine decisions. While it hasn’t been achieved yet, the outlines of success are visible on the ho...
SOUTH SAN FRANCISCO, Calif., July 16, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of.
SOUTH SAN FRANCISCO, Calif., July 15, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.
Q1 2020 CareDx Inc Earnings Call
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary
New Kidney360 Publication Highlights CareDx’s AlloSure is Differentiated as the dd-cfDNA Test of Choice
SOUTH SAN FRANCISCO, Calif., June 22, 2020 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of.